Case Study: Targeting BCMA – Multiple Myeloma
Solutions & Cell Therapy Types Accelerated by IsoPlexis
Pre-clinical Choice Metric
Discover the true function of engineered cell products and the functional subsets that make a difference.
Reveal the most potent candidates in targeting BCMA-Multiple Myeloma
Demonstrated the positive association of polyfunctional strength index (PSI) to the functional enhancement of trimeric APRIL (TriPRIL) CAR-T cells1
The PSI helped correlate uniquely with tumor killing activity against both human cells and mouse models in vitro and in vivo and show improvement difference of TriPRIL CAR-T cells vs. April and conventional BCMA CAR-T cells